Bayer (FRA:BAYN) has been assigned a €76.00 ($88.37) price target by HSBC in a research report issued on Thursday. The brokerage presently has a “neutral” rating on the healthcare company’s stock. HSBC’s target price indicates a potential upside of 12.49% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on BAYN. DZ Bank restated a “buy” rating on shares of Bayer in a report on Monday. Baader Bank set a €123.00 ($143.02) price target on Bayer and gave the stock a “buy” rating in a report on Wednesday, February 27th. Kepler Capital Markets set a €84.00 ($97.67) price target on Bayer and gave the stock a “buy” rating in a report on Wednesday, February 20th. Nord/LB set a €72.00 ($83.72) price target on Bayer and gave the stock a “neutral” rating in a report on Wednesday, February 27th. Finally, Independent Research set a €74.00 ($86.05) price target on Bayer and gave the stock a “neutral” rating in a report on Wednesday, February 27th. Seven equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of €88.67 ($103.11).

BAYN opened at €67.56 ($78.56) on Thursday. Bayer has a 1-year low of €91.58 ($106.49) and a 1-year high of €123.82 ($143.98).

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Read More: What is an SEC Filing?

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.